Previous studies have demonstrated that HER2-positive and triple-negative breast cancers have a higher propensity for brain metastases and may respond differently to SRS compared to hormone receptor-positive subtypes [3,7]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.